← Eichor
Study identifier: NCT04731246 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Video-oculography and Parkinson's Disease

Condition: Parkinson Disease, Idiopathic  ·  Sponsor: Association de Recherche Bibliographique pour les Neurosciences

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015): * the evolution of oculomotricity markers over time. * the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years. * the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography. * the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.

This description comes directly from the study's public registry record.

Talk to the study team

Solange HESSE  ·  +377 99995599  ·  solange.hesse@chpg.mc

Kévin POLET  ·  kevin.polet@chpg.mc

Always discuss trial participation with your own doctor first.

Locations (1)

Centre Mémoire / Centre de Gérontologie Clinique Rainier III / Princess Grace HospitalMonaco, MonacoRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT04731246